Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart for Primary Cutaneous Amyloidosis
NCT07143864Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, double-blind trial in primary cutaneous amyloidosis (PCA) comparing Stapokibart with Placebo (2 arms). Primary endpoint: Amyloidosis Area and Severity Index 75 at 16 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
primary cutaneous amyloidosis (PCA)
Beyond the preview
Go deeper on NCT07143864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143864.